CC chemokine receptor 5: The interface of host immunity and cancer

Disease Markers

Volumn 2014, Issue , 2014, Pages

  Oliveira, Carlos Eduardo Coral De ^a   Oda, Julie Massayo Maeda ^a   Losi Guembarovski, Roberta ^a   Oliveira, Karen Brajão De ^a   Ariza, Carolina Batista ^a   Neto, Jamil Soni ^a   Banin Hirata, Bruna Karina ^a   Watanabe, Maria Angelica Ehara ^a  

^a STATE UNIVERSITY OF LONDRINA   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR5; CCL5 PROTEIN, HUMAN; CCR5 PROTEIN, HUMAN; RANTES;

CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER TISSUE; CARCINOGENESIS; HOST SUSCEPTIBILITY; HUMAN; IMMUNE RESPONSE; MACROPHAGE; MONOCYTE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; ANIMAL; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; NEOPLASMS; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; CHEMOKINE CCL5; HUMANS; IMMUNOTHERAPY; NEOPLASMS; RECEPTORS, CCR5; SIGNAL TRANSDUCTION; T-LYMPHOCYTES, REGULATORY; TUMOR MICROENVIRONMENT;

EID: 84893815024     PISSN: 02780240     EISSN: 18758630     Source Type: Journal    
DOI: 10.1155/2014/126954     Document Type: Review

References (79)

1. Viola A., Luster A. D., Chemokines and their receptors: drug targets in immunity and inflammation. Annual Review of Pharmacology and Toxicology 2008 48 171 197 2-s2.0-41149111580 10.1146/annurev.pharmtox.48.121806.154841 (Pubitemid 351756361)
2. Balkwill F., Cancer and the chemokine network. Nature Reviews Cancer 2004 4 7 540 550 2-s2.0-3042822267 (Pubitemid 38868623)
3. Loetscher P., Seitz M., Baggiolini M., Moser B., Interleukin-2 regulates CC chemokine receptor expression and chemotactic responsiveness in T lymphocytes. Journal of Experimental Medicine 1996 184 2 569 577 2-s2.0-0029811908 (Pubitemid 26324110)
4. Allen S. J., Crown S. E., Handel T. M., Chemokine: receptor structure, interactions, and antagonism. Annual Review of Immunology 2007 25 787 820 2-s2.0-34247855761 10.1146/annurev.immunol.24.021605.090529 (Pubitemid 46697924)
5. Mantovani A., The chemokine system: redundancy for robust outputs. Immunology Today 1999 20 6 254 257 2-s2.0-0033152142 10.1016/S0167-5699(99) 01469-3 (Pubitemid 29258161)
6. Koizumi K., Hojo S., Akashi T., Yasumoto K., Saiki I., Chemokine receptors in cancer metastasis and cancer cell-derived chemokines in host immune response. Cancer Science 2007 98 11 1652 1658 2-s2.0-34748820033 10.1111/j.1349-7006.2007.00606.x (Pubitemid 47487897)
7. O'Hayre M., Salanga C. L., Handel T. M., Allen S. J., Chemokines and cancer: migration, intracellular signalling and intercellular communication in the microenvironment. Biochemical Journal 2008 409 3 635 649 2-s2.0-38949205852 10.1042/BJ20071493 (Pubitemid 351214190)
8. Raport C. J., Gosling J., Schweickart V. L., Gray P. W., Charo I. F., Molecular cloning and functional characterization of a novel human CC chemokine receptor (CCR5) for RANTES, MIP-1 β and MIP-1 α Journal of Biological Chemistry 1996 271 29 17161 17166 2-s2.0-0030035550 10.1074/jbc.271.29.17161 (Pubitemid 26244268)
9. Samson M., Labbe O., Mollereau C., Vassart G., Parmentier M., Molecular cloning and functional expression of a new human CC-chemokine receptor gene. Biochemistry 1996 35 11 3362 3367 2-s2.0-0029986131 10.1021/bi952950g (Pubitemid 26092558)
10. Proost P., Wuyts A., van Damme J., The role of chemokines in inflammation. Clinical and Experimental Medicine 1996 26 4 211 223 2-s2.0-2442599610
11. Spagnolo P., Renzoni E. A., Wells A. U., Copley S. J., Desai S. R., Sato H., Grutters J. C., Abdallah A., Taegtmeyer A., Du Bois R. M., Welsh K. I., C-C chemokine receptor 5 gene variants in relation to lung disease in sarcoidosis. American Journal of Respiratory and Critical Care Medicine 2005 172 6 721 728 2-s2.0-24944565902 10.1164/rccm.200412-1707OC (Pubitemid 41324227)
12. Chelli M., Alizon M., Determinants of the trans-dominant negative effect of truncated forms of the CCR5 chemokine receptor. Journal of Biological Chemistry 2001 276 50 46975 46982 2-s2.0-0035861556 10.1074/jbc.M106432200
13. Kuipers H. F., Biesta P. J., Montagne L. J., Haastert E. S. V., Van Der Valk P., Van Den Elsen P. J., CC chemokine receptor 5 gene promoter activation by the cyclic AMP response element binding transcription factor. Blood 2008 112 5 1610 1619 2-s2.0-52649145772 10.1182/blood-2008-01-135111
14. Wierda R. J., Kuipers H. F., van Eggermond M. C., Epigenetic control of CCR5 transcript levels in immune cells and modulation by small molecules inhibitors. Journal of Cellular and Molecular Medicine 2011 16 8 1866 1877 10.1111/j.1582-4934.2011.01482.x
15. Nanki T., Lipsky P. E., Stimulation of T-cell activation by CXCL12/stromal cell derived factor-1 involves a G-protein mediated signaling pathway. Cellular Immunology 2001 214 2 145 154 2-s2.0-0035894948 10.1006/cimm.2001.1890 (Pubitemid 34499468)
16. Sallusto F., Lenig D., Mackay C. R., Lanzavecchia A., Flexible programs of chemokine receptor expression on human polarized T helper 1 and 2 lymphocytes. Journal of Experimental Medicine 1998 187 6 875 883 2-s2.0-0032536869 10.1084/jem.187.6.875 (Pubitemid 28141661)
17. Wallace G. R., John Curnow S., Wloka K., Salmon M., Murray P. I., The role of chemokines and their receptors in ocular disease. Progress in Retinal and Eye Research 2004 23 4 435 448 2-s2.0-3042625946 10.1016/j.preteyeres.2004. 04.004 (Pubitemid 38829451)
18. Panzer U., Schneider A., Steinmetz O. M., Wenzel U., Barth P., Reinking R., Becker J. U., Harendza S., Zahner G., Fischereder M., Schlöndorf D., Ostendorf T., Floege J., Helmchen U., Stahl R. A. K., Krämer B. K., The chemokine receptor 5 Delta32 mutation is associated with increased renal survival in patients with IgA nephropathy. Kidney International 2005 67 75 81 (Pubitemid 40019228)
19. Schlecker E., Stojanovic A., Eisen C., Tumor-infiltrating monocytic myeloid-derived suppressor cells mediate CCR5-dependent recruitment of regulatory T cells favoring tumor growth. Journal of Immunology 2012 189 12 5602 5611
20. Chang L. Y., Lin Y. C., Kang C. W., The indispensable role of CCR5 for in vivo suppressor function of tumor-derived CD103+ effector/memory regulatory T cells. Journal of Immunology 2012 189 567 574 10.4049/jimmunol.1200266
21. Hirahara K., Poholek A., Vahedi G., Mechanisms underlying helper T-cell plasticity: implications for immune-mediated disease. The Journal of Allergy and Clinical Immunology 2013 131 5 1276 1287 10.1016/j.jaci.2013.03.015
22. Nakayamada S., Takahashi H., Kanno Y., O'Shea J. J., Helper T cell diversity and plasticity. Current Opinion in Immunology 2012 24 297 2-s2.0-84856978626 10.1016/j.coi.2012.01.014
23. Weiss E.-M., Schmidt A., Vobis D., Garbi N., Lahl K., Mayer C. T., Sparwasser T., Ludwig A., Suri-Payer E., Oberle N., Krammer P. H., Foxp3-mediated suppression of cd95l expression confers resistance to activation-induced cell death in regulatory T cells. Journal of Immunology 2011 187 4 1684 1691 2-s2.0-80051950281 10.4049/jimmunol.1002321
24. Wong M. M., Fish E. N., Chemokines: attractive mediators of the immune response. Seminars in Immunology 2003 15 1 5 14 2-s2.0-0037300378 10.1016/S1044-5323(02)00123-9 (Pubitemid 36092174)
25. Aliberti J., Reis E Sousa C., Schito M., Hieny S., Wells T., Huffnagle G. B., Sher A., CCR5 provides a signal for microbial induced production of IL-12 by CD8 α + dendritic cells. Nature Immunology 2000 1 1 83 87 2-s2.0-0034231216
26. Tyner J. W., Uchida O., Kajiwara N., Kim E. Y., Patel A. C., O'Sullivan M. P., Walter M. J., Schwendener R. A., Cook D. N., Danoff T. M., Holtzman M. J., CCL5-CCR5 interaction provides antiapoptotic signals for macrophage survival during viral infection. Nature Medicine 2005 11 11 1180 1187 2-s2.0-30744447910 10.1038/nm1303 (Pubitemid 43093665)
27. Bonecchi R., Bianchi G., Bordignon P. P., D'Ambrosio D., Lang R., Borsatti A., Sozzani S., Allavena P., Gray P. A., Mantovani A., Sinigaglia F., Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s. Journal of Experimental Medicine 1998 187 1 129 134 2-s2.0-0031963014 10.1084/jem.187.1.129 (Pubitemid 28044828)
28. Amedei A., Prisco D., D'Elios M. M., The use of cytokines and chemokines in the cancer immunotherapy. Recent Patents on Anti-Cancer Drug Discovery 2013 8 2 126 142
29. Cocchi F., DeVico A. L., Garzino-Demo A., Arya S. K., Gallo R. C., Lusso P., Identification of RANTES, MIP-1 α and MIP-1 β as the major HIV-suppressive factors produced by CD8+ T cells. Science 1995 270 5243 1811 1815 2-s2.0-0029417004
30. Feng H., Zhu X. T., Qi Z. M., Wang Q. H., Wang G. G., Pan Y. Y., Li Y., Zheng L., Jiang Y. J., Shang H., Cui L., Cao Y. M., Transient attenuated Foxp3 expression on CD4+ T cells treated with 7D4 mAb contributes to the control of parasite burden in DBA/2 mice infected with lethal plasmodium chabaudi chabaudi AS. Scandinavian Journal of Immunology 2012 75 1 46 53 2-s2.0-83455235350 10.1111/j.1365-3083.2011.02622.x
31. Vicari A. P., Caux C., Chemokines in cancer. Cytokine and Growth Factor Reviews 2002 13 2 143 154 2-s2.0-0036005889 10.1016/S1359-6101(01)00033-8 (Pubitemid 34229389)
32. Yoshie O., Immune chemokines and their receptors: the key elements in the genesis, homeostasis and function of the immune system. Springer Seminars in Immunopathology 2000 22 4 371 391 2-s2.0-0033635538
33. Yoshie O., Imai T., Nomiyama H., Novel lymphocyte-specific CC chemokines and their receptors. Journal of Leukocyte Biology 1997 62 5 634 644 2-s2.0-0030714683 (Pubitemid 27519774)
34. Ben-Baruch A., The multifaceted roles of chemokines in malignancy. Cancer and Metastasis Reviews 2006 25 3 357 371 2-s2.0-33845535091 10.1007/s10555-006-9003-5 (Pubitemid 44922355)
35. Zlotnik A., Chemokines and cancer. International Journal of Cancer 2006 119 9 2026 2029 2-s2.0-33748873913 10.1002/ijc.22024 (Pubitemid 44423657)
36. Shields J. D., Fleury M. E., Yong C., Tomei A. A., Randolph G. J., Swartz M. A., Autologous chemotaxis as a mechanism of tumor cell homing to lymphatics via interstitial flow and autocrine CCR7 signaling. Cancer Cell 2007 11 6 526 538 2-s2.0-34249774277 10.1016/j.ccr.2007.04.020 (Pubitemid 46856909)
37. Mañes S., Mira E., Colomer R., Montero S., Real L. M., Gómez-Moutón C., Jiménez-Baranda S., Garzón A., Lacalle R. A., Harshman K., Ruíz A., Martínez-A C., CCR5 expression influences the progression of human breast cancer in a p53-dependent manner. Journal of Experimental Medicine 2003 198 9 1381 1389 2-s2.0-16744362709 10.1084/jem.20030580 (Pubitemid 37392483)
38. Zimmermann T., Moehler M., Gockel I., Sgourakis G. G., Biesterfeld S., Müller M., Berger M. R., Lang H., Galle P. R., Schimanski C. C., Low expression of chemokine receptor CCR5 in human colorectal cancer correlates with lymphatic dissemination and reduced CD8+ T-cell infiltration. International Journal of Colorectal Disease 2010 25 4 417 424 2-s2.0-77953290424 10.1007/s00384-009-0868-y
39. Gonzalez-Martin A., Mira E., Manes S., CCR5 in cancer immunotherapy: more than an, "attractive" receptor for T cells. Oncoimmunology 2012 1 106
40. Azenshtein E., Luboshits G., Shina S., Neumark E., Shahbazian D., Weil M., Wigler N., Keydar I., Ben-Baruch A., The CC chemokine RANTES in breast carcinoma progression: regulation of expression and potential mechanisms of promalignant activity. Cancer Research 2002 62 4 1093 1102 2-s2.0-0036174325 (Pubitemid 34160293)
41. Suffee N., Hlawaty H., Meddahi-Pelle A., RANTES/CCL5-induced pro-angiogenic effects depend on CCR1, CCR5 and glycosaminoglycans. Angiogenesis 2012 15 727 744
42. Gupta G. P., Massagué J., Cancer metastasis: building a framework. Cell 2006 127 4 679 695 2-s2.0-33751252276 10.1016/j.cell.2006.11.001 (Pubitemid 44781029)
43. van Deventer H. W., O'Connor W. Jr., Brickey W. J., Aris R. M., Ting J. P. Y., Serody J. S., C-C chemokine receptor 5 on stromal cells promotes pulmonary metastasis. Cancer Research 2005 65 8 3374 3379 2-s2.0-17144371004 (Pubitemid 40524622)
44. Tang C.-H., Yamamoto A., Lin Y.-T., Fong Y.-C., Tan T.-W., Involvement of matrix metalloproteinase-3 in CCL5/CCR5 pathway of chondrosarcomas metastasis. Biochemical Pharmacology 2010 79 2 209 217 2-s2.0-71749105656 10.1016/j.bcp.2009.08.006
45. Chuang J.-Y., Yang W.-H., Chen H.-T., Huang C.-Y., Tan T.-W., Lin Y.-T., Hsu C.-J., Fong Y.-C., Tang C.-H., CCL5/CCR5 axis promotes the motility of human oral cancer cells. Journal of Cellular Physiology 2009 220 2 418 426 2-s2.0-67649342558 10.1002/jcp.21783
46. Makishima H., Ito T., Momose K., Nakazawa H., Shimodaira S., Kamijo Y., Nakazawa Y., Ichikawa N., Ueno M., Kobayashi H., Kitano K., Saito H., Kiyosawa K., Ishida F., Chemokine system and tissue infiltration in aggressive NK-cell leukemia. Leukemia Research 2007 31 9 1237 1245 2-s2.0-34548041222 10.1016/j.leukres.2006.10.020 (Pubitemid 46873740)
47. Menu E., De Leenheer E., De Raeve H., Coulton L., Imanishi T., Miyashita K., Van Valckenborgh E., Van Riet I., Van Camp B., Horuk R., Croucher P., Vanderkerken K., Role of CCR1 and CCR5 in homing and growth of multiple myeloma and in the development of osteolytic lesions: a study in the 5TMM model. Clinical and Experimental Metastasis 2006 23 5-6 291 300 2-s2.0-33751190044 10.1007/s10585-006-9038-6
48. Aldinucci D., Lorenzon D., Cattaruzza L., Pinto A., Gloghini A., Carbone A., Colombatti A., Expression of CCR5 receptors on Reed-Sternberg cells and Hodgkin lymphoma cell lines: involvement of CCL5/Rantes in tumor cell growth and microenvironmental interactions. International Journal of Cancer 2008 122 4 769 776 2-s2.0-38349059732 10.1002/ijc.23119
49. Wang S.-W., Wu H.-H., Liu S.-C., Wang P.-C., Ou W.-C., Chou W.-Y., Shen Y.-S., Tang C.-H., CCL5 and CCR5 interaction promotes cell motility in human osteosarcoma. PLoS ONE 2012 7 4 2-s2.0-84859613229 10.1371/journal.pone.0035101 e35101
50. Lin S., Wan S., Sun L., Hu J., Fang D., Zhao R., Yuan S., Zhang L., Chemokine C-C motif receptor 5 and C-C motif ligand 5 promote cancer cell migration under hypoxia. Cancer Science 2012 103 5 904 912 2-s2.0-84860251782 10.1111/j.1349-7006.2012.02259.x
51. Wang J., He Q., Shao Y. G., Ji M., Chemokines fluctuate in the progression of primary breast cancer. European Review for Medical and Pharmacological Sciences 2013 17 596
52. Pinilla S., Alt E., Abdul Khalek F. J., Jotzu C., Muehlberg F., Beckmann C., Song Y.-H., Tissue resident stem cells produce CCL5 under the influence of cancer cells and thereby promote breast cancer cell invasion. Cancer Letters 2009 284 1 80 85 2-s2.0-69049098045 10.1016/j.canlet.2009.04.013
53. Karnoub A. E., Dash A. B., Vo A. P., Sullivan A., Brooks M. W., Bell G. W., Richardson A. L., Polyak K., Tubo R., Weinberg R. A., Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 2007 449 7162 557 563 2-s2.0-34948896045 10.1038/nature06188 (Pubitemid 47525152)
54. Jayasinghe M. M., Golden J. M., Nair P., O'Donnell C. M., Werner M. T., Kurt R. A., Tumor-derived CCL5 does not contribute to breast cancer progression. Breast Cancer Research and Treatment 2008 111 3 511 521 2-s2.0-51649098196 10.1007/s10549-007-9802-6
55. Faaij C. M. J. M., Willemze A. J., Révész T., Balzarolo M., Tensen C. P., Hoogeboom M., Vermeer M. H., Van Wering E., Zwaan C. M., Kaspers G. J. L., Story C., Van Halteren A. G. S., Vossen J. M., Egeler R. M., Van Tol M. J. D., Annels N. E., Chemokine/chemokine receptor interactions in extramedullary leukaemia of the skin in childhood AML: differential roles for CCR2, CCR5, CXCR4 and CXCR7. Pediatric Blood and Cancer 2010 55 2 344 348 2-s2.0-77955100333 10.1002/pbc.22500
56. Hoyne G. F., Notch signaling in the immune system. Journal of Leukocyte Biology 2003 74 6 971 981 2-s2.0-0348047540 10.1189/jlb.0303089 (Pubitemid 38040318)
57. Maillard I., Adler S. H., Pear W. S., Notch and the immune system. Immunity 2003 19 6 781 791 2-s2.0-0346849694 10.1016/S1074-7613(03)00325-X (Pubitemid 37542299)
58. Sanchez-Dominguez R., Pereira-Mendez S., Gomez A., Notch signals contribute to preserve the multipotentiality of human CD34(+)CD38(-)CD45RA(-) CD90(+) hematopoietic progenitors by maintaining T cell lineage differentiation potential. Experimental Hematology 2012 40 12 983 993 10.1016/j.exphem.2012.08. 009
59. Mirandola L., Chiriva-Internati M., Montagna D., Locatelli F., Zecca M., Ranzani M., Basile A., Locati M., Cobos E., Kast W. M., Asselta R., Paraboschi E. M., Comi P., Chiaramonte R., Notch1 regulates chemotaxis and proliferation by controlling the CC-chemokine receptors 5 and 9 in T cell acute lymphoblastic leukaemia. Journal of Pathology 2012 226 5 713 722 2-s2.0-84858000851 10.1002/path.3015
60. Watanabe M. A. E., Oda J. M. M., Amarante M. K., Cesar Voltarelli J., Regulatory T cells and breast cancer: implications for immunopathogenesis. Cancer and Metastasis Reviews 2010 29 4 569 579 2-s2.0-78449285435 10.1007/s10555-010-9247-y
61. Belkaid Y., Rouse B. T., Natural regulatory T cells in infectious disease. Nature Immunology 2005 6 4 353 360 2-s2.0-16844369607 10.1038/ni1181 (Pubitemid 41716772)
62. Yurchenko E., Tritt M., Hay V., Shevach E. M., Belkaid Y., Piccirillo C. A., CCR5-dependent homing of naturally occurring CD4+ regulatory T cells to sites of Leishmania major infection favors pathogen persistence. Journal of Experimental Medicine 2006 203 11 2451 2460 2-s2.0-33750530395 10.1084/jem.20060956 (Pubitemid 44664615)
63. Kang S. G., Piniecki R. J., Hogenesch H., Lim H. W., Wiebke E., Braun S. E., Matsumoto S., Kim C. H., Identification of a chemokine network that recruits FoxP3(+) regulatory T cells into chronically inflamed intestine. Gastroenterology 2007 132 3 966 981 2-s2.0-33947427950 10.1053/j.gastro.2007.01. 008 (Pubitemid 46454268)
64. Kallikourdis M., Andersen K. G., Welch K. A., Betz A. G., Alloantigen-enhanced accumulation of CCR5+"effector" regulatory T cells in the gravid uterus. Proceedings of the National Academy of Sciences of the United States of America 2007 104 2 594 599 2-s2.0-33846330505 10.1073/pnas.0604268104 (Pubitemid 46123070)
65. Oda J. M. M., Guembarovski R. L., Watanabe M. A. E., Transforming Growth Factor b (TGF-b) and Regulatory T Cells, (Treg): the interface of tumor and host immunity. European Journal of Clinical & Medical Oncology 2012 4 6
66. Tan M. C. B., Goedegebuure P. S., Belt B. A., Flaherty B., Sankpal N., Gillanders W. E., Eberlein T. J., Hsieh C.-S., Linehan D. C., Disruption of CCR5-dependent homing of regulatory T cells inhibits tumor growth in a murine model of pancreatic cancer. Journal of Immunology 2009 182 3 1746 1755 2-s2.0-63149148047
67. Chakraborty R., Rooney C., Dotti G., Savoldo B., Changes in chemokine receptor expression of regulatory t cells after ex vivo culture. Journal of Immunotherapy 2012 35 4 329 336 2-s2.0-84859893984 10.1097/CJI.0b013e318255adcc
68. Liotta F., Gacci M., Frosali F., Querci V., Vittori G., Lapini A., Santarlasci V., Serni S., Cosmi L., Maggi L., Angeli R., Mazzinghi B., Romagnani P., Maggi E., Carini M., Romagnani S., Annunziato F., Frequency of regulatory T cells in peripheral blood and in tumour-infiltrating lymphocytes correlates with poor prognosis in renal cell carcinoma. British Journal of Urology International 2011 107 9 1500 1506 2-s2.0-79953810395 10.1111/j.1464-410X.2010. 09555.x
69. Oldham K. A., Parsonage G., Bhatt R. I., Wallace D. M. A., Deshmukh N., Chaudhri S., Adams D. H., Lee S. P., T lymphocyte recruitment into renal cell carcinoma tissue: a role for chemokine receptors CXCR3, CXCR6, CCR5, and CCR6. European Urology 2012 61 2 385 394 2-s2.0-83955163746 10.1016/j.eururo.2011.10. 035
70. Chang L.-Y., Lin Y.-C., Mahalingam J., Huang C.-T., Chen T.-W., Kang C.-W., Peng H.-M., Chu Y.-Y., Chiang J.-M., Dutta A., Day Y.-J., Chen T.-C., Yeh C.-T., Lin C.-Y., Tumor-derived chemokine CCL5 enhances TGF- β -mediated killing of CD8+ T cells in colon cancer by T-regulatory cells. Cancer Research 2012 72 5 1092 1102 2-s2.0-84857754240 10.1158/0008-5472.CAN-11-2493
71. Khamis Z. I., Sahab Z. J., Sang Q. X., Active roles of tumor stroma in breast cancer metastasis. International Journal of Breast Cancer 2012 2012 10 574025 10.1155/2012/574025
72. Fujimura T., Mahnke K., Enk A. H., Myeloid derived suppressor cells and their role in tolerance induction in cancer. Journal of Dermatological Science 2010 59 1 1 6 2-s2.0-77953611288 10.1016/j.jdermsci.2010.05.001
73. Robinson S. C., Scott K. A., Wilson J. L., Thompson R. G., Proudfoot A. E. I., Balkwill F. R., A chemokine receptor antagonist inhibits experimental breast tumor growth. Cancer Research 2003 63 23 8360 8365 2-s2.0-0346365367 (Pubitemid 37549490)
74. Velasco-Velazquez M., Pestell R. G., The CCL5/CCR5 axis promotes metastasis in basal breast cancer. Oncoimmunology 2013 2 e23660
75. Velasco-Velazquez M., Jiao X., De La Fuente M., CCR5 antagonist blocks metastasis of basal breast cancer cells. Cancer Research 2012 72 3839 10.1158/0008-5472.CAN-11-3917
76. Amarante M. K., Oda J. M. M., Reiche E. M. V., Morimoto H. K., Aoki M. N., Watanabe M. A. E. W., Human endogenous RNAs: implications for the immunomodulation of Toll-like receptor 3. Experimental and Therapeutic Medicine 2011 2 5 925 929 2-s2.0-79960228452 10.3892/etm.2011.303
77. Aoki M. N., Amarante M. K., Oda J. M. M., Watanabe M. A. E., Caveolin involvement and modulation in breast cancer. Mini-Reviews in Medicinal Chemistry 2011 11 13 1143 1152 2-s2.0-80054057428 10.2174/138955711797655344
78. de Oliveira K. B., Guembarovski R. L., Guembarovski A. M., CXCL12, CXCR4 and IFNgamma genes expression: implications for proinflammatory microenvironment of breast cancer. Clinical and Experimental Medicine 2012 13 3 211 219
79. Do Val Carneiro J. L., Nixdorf S. L., Mantovani M. S., Da Silva Do Amaral Herrera A. C., Aoki M. N., Amarante M. K., Fabris B. A., Pelegrinelli Fungaro M. H., Ehara Watanabe M. A., Plasma malondialdehyde levels and CXCR4 expression in peripheral blood cells of breast cancer patients. Journal of Cancer Research and Clinical Oncology 2009 135 8 997 1004 2-s2.0-68149176869 10.1007/s00432-008-0535-7